Phase II trial evaluating the long-term efficacy and peripheral sensory neuropathy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer

• Published in: Scientific reports Vol. 14; no. 1; pp. 26434 - 7
• Main Authors: Hata, Taishi, Uemura, Mamoru, Danno, Katsuki, Yoshioka, Shinichi, Matsuda, Chu, Kagawa, Yoshinori, Shingai, Tatsushi, Suzuki, Yozo, Tei, Mitsuyoshi, Tanida, Tsukasa, Komori, Takamichi, Okamura, Shu, Ota, Hirofumi, Takemoto, Hiroyoshi, Ogino, Takayuki, Miyoshi, Norikatsu, Yamamoto, Hirofumi, Murata, Kohei, Doki, Yuichiro, Eguchi, Hidetoshi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 02.11.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67; 631/67/1059; 631/67/1059/99; Adjuvant chemotherapy; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer therapies; Capecitabine - administration & dosage; Capecitabine - adverse effects; Capecitabine - therapeutic use; Chemotherapy, Adjuvant - adverse effects; Colon cancer; Colonic Neoplasms - drug therapy; Colonic Neoplasms - pathology; Colorectal cancer; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Disease management; Disease-Free Survival; East Asian People; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Fluorouracil - analogs & derivatives; Fluorouracil - therapeutic use; Humanities and Social Sciences; Humans; Japan; Japanese; Male; Medical prognosis; Middle Aged; multidisciplinary; Neoplasm Staging; Neuropathy; Oxaliplatin; Oxaliplatin - administration & dosage; Oxaliplatin - adverse effects; Oxaliplatin - therapeutic use; Oxaloacetates; Patients; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - etiology; Peripheral neuropathy; Peripheral sensory neuropathy; Prospective Studies; Science; Science (multidisciplinary); Survival; Treatment Outcome; XELOX; Japan; XELOX; Adjuvant chemotherapy; Peripheral sensory neuropathy; Japanese

Adjuvant oxaliplatin plus capecitabine (XELOX) therapy is recommended for patients with curatively resected colon cancer. However, prospective data on its practical application in Japanese patients are limited. Therefore, we aimed to conduct a long-term clinical evaluation of the efficacy and safety...